Rise and fall and Triumph!? As Oncopeptides AB (publ) (STO:ONCO) gains 13%, insiders who bought last year may be wishing they had bet higher
As Oncopeptides AB (publ) (STO:ONCO) gains 13%, insiders who bought last year may be wishing they had bet higher
Their peptide(prodrug) conjugate was approved early 2021 and then withdrawn voluntarily late 2021 in the US due to safety concerns, last month it got signed off by CHMP now awaiting formal approval in Europe and further conversations with the FDA in order to restart the commercialization in the US.
The stock peaked in 2018 at 195 or so SEK well before the approval got hammered due to departure from the US market to 5 or so SEK in late 2021 now it has appreciated YTD by over 400 per cent due to recent positive developments. So insiders got it wrong as they should accumulate more, point is in drug development the biotech companies can get punished badly or rewarded handsomely in short period of time and even insiders can’t time the market.
I certainly hope the recent insider selling proves to be an enormous mistake which can easily be the case! The other point is in case of Oncopeptides interestingly the valuation jumped well before approval of the drug so as many mentioned potentially if and when THTX’s R&D programs starting to deliver the goods backed by well thought promotions/marketing I really hope the battered long term investors of this company get the belated financial rewards they deserve.
As for sales me, Palinc and too few remaining believers still haven’t thrown in the towel the logic is simple a drug administered by IV(Trogarzo)during the pandemic wouldn’t/shouldn’t have a chance to reach its financial potentials and as per Egrifta with all the recent scientific updates/discoveries and ongoing research opening up possible multiple therapeutic effects (increasing financial prospects) on various conditions again one can only rightfully assume the sales get boosted going forward. As per Paul and his achievements so far I believe the finger should be pointed at our outdated board with outdated mentality/strategies so I do what I have been doing for the last couple of years which was keep voting out the dinosaurs running this company because as an proactive investor trying you name it to make a difference from ongoing research to actively communicating with the company for as long as I remember yet no changes that’s all I, you can do.